Penumbra, Inc. (FRA:0P8)

Market Cap	11.81B +20.9%
Revenue (ttm)	1.14B +14.6%
Net Income	139.80M +374.8%
EPS	3.53 +367.3%
Shares Out	n/a
PE Ratio	84.45
Forward PE	75.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201
Average Volume	21
Open	296.20
Previous Close	297.30
Day's Range	296.20 - 302.30
52-Week Range	193.10 - 306.40
Beta	n/a
RSI	65.13
Earnings Date	Feb 23, 2026

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2004
• Employees: 4,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0P8

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Financial numbers in USD